Skip to main content

Corneal Persistent Epithelial Defect clinical trials at UCLA

2 research studies open to eligible people

Showing trials for
  • KPI-012 Ophthalmic Solution in Participants With PCED

    open to eligible people ages 18 years and up

    The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.

    Los Angeles, California and other locations

  • NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Chemical and/or Thermal Injuries

    open to all eligible people

    This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care for at least 14 days. It will assess the efficacy and safety of Nexagon® (lufepirsen) plus standard of care versus NEXAGON-vehicle (placebo) plus standard of care. The recovery of the corneal epithelium will be the primary outcome measure, defined as a cornea that re-epithelializes by Day 28 of treatment and remains re-epithelialized for at least a further 28 days.

    Los Angeles, California and other locations

Our lead scientists for Corneal Persistent Epithelial Defect research studies include .

Last updated: